Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

4904 - Molecular characterization of metastatic urothelial carcinoma (mUC) in prior or current smokers (PCS) vs non-smokers (NS)

Date

30 Sep 2019

Session

Poster Display session 3

Topics

Tumour Site

Urothelial Cancer

Presenters

Victor Sacristan Santos

Citation

Annals of Oncology (2019) 30 (suppl_5): v356-v402. 10.1093/annonc/mdz249

Authors

V. Sacristan Santos1, J. Esther2, B.L. Maughan3, S. Wesolowski4, E. Lin5, A. Hahn1, D. Sirohi6, N. Rathi7, U. Swami8, R. Nussenzveig1, N. Agarwal9

Author affiliations

  • 1 Genitourinary Oncology Program, Huntsman Cancer Institute, University of Utah, 84112 - Salt Lake City/US
  • 2 Medical Oncology, University of Utah, 84112 - Salt Lake City/US
  • 3 Medical Oncology, Huntsman Cancer Institute, 84112 - Salt Lake City/US
  • 4 Bioinformatics, University of Utah, 84112 - Salt Lake City/US
  • 5 Medical Oncology, Huntsman Cancer Institute, University of Utah, 84112 - Salt Lake City/US
  • 6 Patology, Huntsman Cancer Institute, University of Utah, 84112 - Salt Lake City/US
  • 7 Dept. Of Oncology, Huntsman Cancer Institute, 84112 - Salt Lake City/US
  • 8 Oncology/ Internal Medicine, University of Iowa Hospitals and clinics, 52242 - Iowa city/US
  • 9 Oncology/ Internal Medicine, Huntsman Cancer Institute, 84112 - Salt Lake City/US

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4904

Background

Even though smoking is one of the most recognized risk factors, NS also develop mUC. Identifying molecular drivers of disease progression in NS have the potential to provide novel targets for drug development. We hypothesized that there will be a difference in genomic profile of mUC in NS vs PCS.

Methods

Tumour tissue undergoing comprehensive genomic profiling (CGP) from patients with mUC were included from NS and age matched PCS within the same time period (2014-19). Clinical and CGP data were retrospectively collected. CGP was performed using FoundationOne (Foundation Medicine, Cambridge, MA), which provides exonic coverage of 315 genes.

Results

See table.Table:

943P

Non-smokerSmokerP value
Median age at diagnosis, years (range)66.5 (33-86)67 (35-85)0.94
Site of primary0.009
Bladder37 (80%)39 (100%)
Upper tract9 (19.6%)0
Urethral1 (<1%)0
Gender0.001
Male3238
Female141
Median number of genomic alterations (range)7 (1-17)7 (1-18)0.26
MLL2 gene alteration1110.01

Conclusions

While the overall number of genomic alteration per patient and alteration frequencies were similar in NS vs PCS, we found a significantly higher frequency of MLL2 alterations in NS (p < 0.05). This finding is in agreement with previous reports of MLL2 alterations in UC; however, its significantly higher prevalence in NS is a novel finding and may suggest different oncogenic pathways in NS. It’s interesting to note that MLL2 alterations have been reported as drivers of self-renewal in bladder cancer stem cells (Yang et al, Euro Urol 2017, PMID 27387124).

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Huntsman Cancer Institute.

Funding

Has not received any funding.

Disclosure

B.L. Maughan: Advisory / Consultancy: Peloton Therapeutics; Advisory / Consultancy: BMS; Advisory / Consultancy: Tempus; Advisory / Consultancy: Bayer; Advisory / Consultancy: Exelixis; Advisory / Consultancy: Janssen Oncology; Advisory / Consultancy: Astellas Pharma. N. Agarwal: Advisory / Consultancy: Astellas; Honoraria (institution), Advisory / Consultancy: BMS; Honoraria (institution), Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Argos; Honoraria (institution), Advisory / Consultancy: Bayer; Honoraria (institution), Advisory / Consultancy: Exelixis; Honoraria (institution), Advisory / Consultancy: Eisai; Honoraria (institution), Advisory / Consultancy: Eli Lilly; Advisory / Consultancy: Foundation One; Honoraria (institution), Advisory / Consultancy: Clovis; Honoraria (institution), Advisory / Consultancy: Merck; Honoraria (institution), Advisory / Consultancy: Medivation; Honoraria (institution), Advisory / Consultancy: Janssen; Honoraria (institution), Advisory / Consultancy: Novartis; Honoraria (institution), Advisory / Consultancy: Pfizer; Honoraria (institution), Advisory / Consultancy: Nektar; Honoraria (institution), Advisory / Consultancy: Genentech; Honoraria (institution), Advisory / Consultancy: EMD Serono; Advisory / Consultancy: Pharmacyclics; Honoraria (institution): Sanofi. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.